Kura Oncology (NASDAQ:KURA) Insider Sells $224,462.58 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Francis Burrows sold 20,726 shares of the firm’s stock in a transaction that occurred on Thursday, September 24th. The shares were sold at an average price of $10.83, for a total value of $224,462.58. Following the completion of the sale, the insider owned 42,327 shares in the company, valued at approximately $458,401.41. This represents a 32.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kura Oncology Price Performance

Shares of Kura Oncology stock opened at $10.76 on Monday. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 4.71. Kura Oncology, Inc. has a 1-year low of $7.36 and a 1-year high of $13.90. The business’s fifty day moving average price is $11.22 and its two-hundred day moving average price is $10.14. The company has a market capitalization of $957.21 million, a P/E ratio of -3.19 and a beta of 0.44.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.11. The company had revenue of $20.87 million during the quarter, compared to analysts’ expectations of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. As a group, research analysts forecast that Kura Oncology, Inc. will post -3.25 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. CLSA set a $24.00 price target on Kura Oncology in a research note on Thursday, June 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research note on Thursday, June 4th. Morgan Stanley set a $24.00 price objective on Kura Oncology in a report on Monday, August 24th. Sanford C. Bernstein set a $24.00 target price on Kura Oncology in a report on Monday, June 15th. Finally, Citizens Jmp reissued a “market outperform” rating and issued a $24.00 price target on shares of Kura Oncology in a report on Monday, August 24th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $25.40.

Institutional Investors Weigh In On Kura Oncology

Several large investors have recently modified their holdings of KURA. IFP Advisors Inc raised its position in shares of Kura Oncology by 115.3% during the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after purchasing an additional 1,284 shares during the period. Allworth Financial LP lifted its holdings in shares of Kura Oncology by 59.9% during the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after purchasing an additional 1,553 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Kura Oncology by 49.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock valued at $60,000 after purchasing an additional 1,888 shares during the period. Pictet Asset Management Holding SA acquired a new position in shares of Kura Oncology in the 1st quarter valued at $96,000. Finally, E Fund Management Co. Ltd. purchased a new position in Kura Oncology in the 2nd quarter worth about $132,000.

About Kura Oncology

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.